Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis : Controlled Clinical Trial With Efficacy Assessment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs ECCS 50 (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Acronyms SCLERADEC II
- 13 Nov 2017 French regulatory authorities approved a 3rd center (Hopital Saint-Louis, Paris) to add to the 2 centers (Assistance Publique Hopitaux de Marseille and CHU de Rouen) for this trial, as reported in a Cytori Therapeutics media release. The Marseille investigators anticipate completing enrollment by the end of 2017.
- 09 Nov 2017 According to a Cytori Therapeutics media release, status changed from recruiting to active, no longer recruiting.
- 14 Jun 2017 According to a Cytori Therapeutics media release, updates from the study will be presented at the Annual European Congress of Rheumatology (EULAR 2017).